Construction of a replication-competent hepatitis B virus vector carrying secreted luciferase transgene and establishment of new hepatitis B virus replication and expression cell lines

Figure 4 Drug susceptibility testing for the new hepatitis B virus -NLuc-35 cell lines. A: Effect of lamivudine on luciferase expression in hepatitis B virus (HBV)-NLuc-35 cell lines. HBV-NLuc-35 cell lines were treated with increasing concentrations of lamivudine (0, 0.1, 0.5, 2.5, 5.0, 12.5, and 25.0 µM). After 72 h, luciferase expression in the supernatant was detected with Nano-Glo luciferase assay reagent; B: Cell line-borne HBV affected by lamivudine. The number of copies of HBV DNA in the supernatant was measured by qPCR; C: Effect of IFN-α on HBV-NLuc-35 cell lines. HBV-NLuc-35 cell lines were inoculated with 3000 IU/mL IFN-α (down line) or untreated (up line), and luciferase expression in the supernatant was detected at the indicated time points (24, 48, 72, 96, and 120 h). HBV: Hepatitis B virus; RUL: Relative light unit.